Neuroscience Today—January 28, 2026

LucidQuest

4 hours ago

This weekly Neurology update covers key developments across clinical research, market access, and investor sentiment, including trial initiations, access expansions, and signals shaping future CNS innovation.

In Today’s Newsletter

Dive deeper

🧪 Neurocrine starts Phase 2 for NBI-1065890 in tardive dyskinesia [1] [US • 26 Jan 2026]

https://www.prnewswire.com/news-releases/neurocrine-biosciences-initiates-phase-2-clinical-study-evaluating-nbi-1065890-in-adults-with-tardive-dyskinesia-302669338.html
Context: Randomized, double-blind, placebo-controlled, ~100 adults with TD; primary endpoint AIMS Items 1–7 change at Week 8.
Key point: NBI-1065890 is a selective VMAT2 inhibitor designed for potentially longer-acting TD options.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 BioNxt sublingual cladribine ODF boosts exposure in pigs ~40% vs tablet [2] [Canada • 21 Jan 2026]

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionxt-reports-final-preclinical-results-demonstrating-approximately-1129562
Context: Single-dose comparative study in adult miniature pigs; AUC 0–48 h measured with validated methods.
Key point: Sublingual ODF AUC 39.46 ng·h/mL vs 28.11 ng·h/mL for tablet, supporting progression to human PK.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧠 “Gold rush” in brain science, per JPM26 investor sentiment [3] [22 Jan 2026]

https://www.biospace.com/drug-development/the-new-gold-rush-in-brain-science
Context: VCs cite biomarkers, brain mapping, AI, and aging demographics; note 2025 CNS deal flow and select clinical failures.
Key point: Momentum spans neuro/CNS drugs and neurotech, including non-implantable stimulation and neuroAI.
Implication: Signals pipeline investment and modality expansion.

☢️ Plus Therapeutics sets 2026 REYOBIQ and CNSide milestones [4] [US • 22 Jan 2026]

https://www.manilatimes.net/2026/01/22/tmt-newswire/globenewswire/plus-therapeutics-provides-business-update-on-reyobiq-clinical-program-and-us-cnside-commercialization/2263510
Context: Company update includes financing extension and commercialization plans.
Key point: Targets ReSPECT-LM Phase 2 dose/interval data Q3 2026, ReSPECT-GBM Phase 2 completion and FDA EOP meeting with data Q4 2026, PBC Phase 1 start, manufacturing scale-up, and payer coverage goals.
Implication: Signals pipeline investment and modality expansion.

🧩 Re:Cognition Health offers Medicare-covered Leqembi/Kisunla at 4 US sites [5] [US • 22 Jan 2026]

https://www.prnewswire.com/news-releases/recognition-health-announces-medicare-coverage-for-fda-approved-early-stage-alzheimers-disease-treatments-at-its-four-us-clinics-302667061.html
Context: Clinics in Fairfax VA, Chicago IL, Houston TX, and Fort Worth TX; experience administering >11,500 ATT doses across US/UK.
Key point: Medicare coverage now available for eligible early-stage AD patients receiving lecanemab or donanemab at these centers.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

TD pipeline diversification could shape next-gen VMAT2 options in a mature class.
Alternative cladribine delivery may address adherence and variability, pending human PK.
Investor appetite in neuro/CNS and neurotech suggests sustained BD and capital flow.
Radiotherapeutics and CSF diagnostics progress toward clearer clinical and commercial pathways.
Medicare-enabled access may bring real-world uptake for disease-modifying AD therapies.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What is NBI-1065890 and how is it being tested?

A selective VMAT2 inhibitor from Neurocrine, now in a Phase 2, randomized, double-blind, placebo-controlled TD study (~100 adults) with AIMS change at Week 8 as the primary endpoint [1].

How much higher was cladribine exposure with BioNxt’s ODF vs tablet?

Approximately 40% higher in pigs, with AUC 0–48 h 39.46 ng·h/mL for ODF vs 28.11 ng·h/mL for tablet under study conditions; human PK is planned next [2].

What are Plus Therapeutics’ key 2026 targets for REYOBIQ and CNSide?

ReSPECT-LM Phase 2 dose/interval data in Q3 2026, ReSPECT-GBM Phase 2 completion with FDA end-of-phase meeting and data in Q4 2026, start ReSPECT-PBC Phase 1, manufacturing scale-up, and expanded payer coverage for CNSide [4].

Where can Medicare-covered Leqembi/Kisunla be accessed via Re:Cognition Health?

Clinics in Fairfax VA, Chicago IL, Houston TX, and Fort Worth TX now offer Medicare-covered treatment for eligible early-stage AD patients [5].

What is driving investor interest in neuro/CNS and neurotech in 2026?

Advances in biomarkers and brain mapping, aging demographics, and notable deal activity, alongside growth in non-implantable neurostimulation and neuroAI, despite recent clinical setbacks [3].

Entities / Keywords

Neurocrine Biosciences; NBI-1065890; VMAT2 inhibitor; tardive dyskinesia; AIMS.
BioNxt Solutions; cladribine; sublingual ODF; AUC; pharmacokinetics; Multiple Sclerosis.
BioSpace Insights; neurotech; neuromodulation; neuroAI; CNS M&A.
Plus Therapeutics; REYOBIQ; ReSPECT-LM; ReSPECT-GBM; ReSPECT-PBC; CNSide; radiopharmaceuticals; CSF diagnostics.
Re:Cognition Health; Leqembi (lecanemab); Kisunla (donanemab); Medicare coverage; early-stage Alzheimer’s disease.